Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial
dc.contributor.author | Armstrong, Anne C | |
dc.contributor.author | Clay, Vanessa | |
dc.date.accessioned | 2019-09-11T09:09:20Z | |
dc.date.available | 2019-09-11T09:09:20Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Armstrong AC, Clay V. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. Future Oncol. 2019;15(20):2327-35. | en |
dc.identifier.pmid | 31304797 | en |
dc.identifier.doi | 10.2217/fon-2018-0067 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622050 | |
dc.description.abstract | Breast cancer remains a leading cause of death worldwide. Our increased understanding of cellular mechanisms inherent to cancer has led to the development of new therapeutic targets. One such therapy is that of poly(ADP-ribose) polymerase (PARP) inhibitors, with PARP playing a key role in the repair of single stranded DNA breaks. The development of drugs able to inhibit PARP led to their investigation in tumors that have defective DNA repair, including that of BRCA1/2-associated cancers. The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutatioN This article will review the findings and potential implications of the trial. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.2217/fon-2018-0067 | en |
dc.title | Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester M20 4BX, UK | en |
dc.identifier.journal | Future Oncology | en |
dc.description.note | en] |